Eton Pharmaceuticals Q2 2024 GAAP EPS $(0.12) Misses $(0.07) Estimate, Sales $9.074M Beat $8.800M Estimate
Author: Benzinga Newsdesk | August 08, 2024 05:12pm
Eton Pharmaceuticals (NASDAQ:
ETON) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.07) by 71.43 percent. The company reported quarterly sales of $9.074 million which beat the analyst consensus estimate of $8.800 million by 3.11 percent. This is a 24.36 percent decrease over sales of $11.997 million the same period last year.
Posted In: ETON